Abstract: both areas were combined, there was a significant difference between stage 1 vs stage 3 (p<0.011),stage 1 vs stage 4 (p< 0.005) and stage 0 vs stage 4 (p< 0.033).HRI measurements: HRI measurements for patients with <5% steatosis vs those with >5% steatosis were different (P<0.0002).Summary: a) SWE can distinguish normal liver/mild fibrosis from cirrhosis in both non-OLT and OLT patents.b) BMI>40 may affect SWE measurements.c) HRI can be used to identify patients with clinically significant steatosis (>5%).Conclusions: SWE and HRI measurements are non-invasive methods that can assist in clinical decision making in the assessment of fibrosis and steatosis in both OLT and non-OLT patients although caution should be exercised over the interpretation of these measurements in patients with a BMI>40.